Prostate cancer
278 results
1 - 100
Better estimate of prostate cancer risk based on the number of close relatives with prostate cancer and their age at diagnosis- PSA screening for prostate cancer not recommended (USPSTF)
- PREDICT Prostate online risk score accurately predicts the prognosis for men with nonmetastatic prostate cancer
- Quality of life varies after different prostate cancer treatments
- Vitamin E supplementation increases risk of prostate cancer
- Hormones + radiation decrease mortality compared with radiation in prostate cancer
- Ask-tell-ask approach to discussing prostate cancer screening
- Increased vegetable consumption does not decrease prostate cancer progression
- Men with localized prostate cancer have inaccurate perceptions of their prognosis
- Prostate cancer screening increases harm risk without decreasing mortality
- Dutasteride slows progression in men with low-grade prostate cancer (REDEEM)
- Observation = radical prostatectomy for most pts with localized prostate cancer (PIVOT)
- Finasteride prevents low-grade prostate cancers, but does not reduce mortality
- The full truth about prostate cancer screening is suppressed again (ERSPC)
- Approximately 12% of men regret prostate cancer treatment decisions (HCaP-NC)
- MA: Low-quality evidence finds DRE screening for prostate cancer inaccurate
- Sexual, urinary, and bowel dysfunction common after treatment for localized prostate cancer
- Have the USPSTF recommendations against screening caused more aggressive prostate cancer?
- 5-a reductase inhibitor use prior to prostate cancer diagnosis is not associated with increased mortality
- Prostate cancer screening: no mortality benefit after 15 years of follow-up (PLCO)
- Prostate cancer screening: no mortality benefit after 13 years of follow-up (PLCO)
- Vitamins E and C and selenium do not reduce risk of prostate or total cancer in men
- Androgen deprivation therapy does not increase risk of CV death in men with prostate cancer
- Prostatectomy for localized prostate cancer causes more functional problems without any survival benefit
- PSA plus MRI-guided biopsy reduces the detection of clinically insignificant prostate cancers more than systematic biopsy
- USPSTF 2018 recommends counseling 55 to 69-year-old men on benefits and harms of prostate cancer screening (C recommendation)